KalVista Pharmaceuticals (NASDAQ:KALV) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

KalVista Pharmaceuticals (NASDAQ:KALV) posted its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04, Yahoo Finance reports.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $12.87 on Friday. The firm has a market capitalization of $542.96 million, a PE ratio of -3.79 and a beta of 0.91. KalVista Pharmaceuticals has a 52-week low of $7.21 and a 52-week high of $16.88. The firm has a fifty day moving average of $13.16 and a 200 day moving average of $12.43.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 2,135 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the transaction, the insider now directly owns 83,745 shares in the company, valued at approximately $1,038,438. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Paul K. Audhya sold 2,135 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the sale, the insider now directly owns 83,745 shares in the company, valued at approximately $1,038,438. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Christopher Yea sold 7,102 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $85,295.02. Following the transaction, the insider now directly owns 84,467 shares in the company, valued at approximately $1,014,448.67. The disclosure for this sale can be found here. Insiders have sold 23,452 shares of company stock worth $282,491 over the last 90 days. Corporate insiders own 12.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on KALV shares. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday. Cantor Fitzgerald raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 26th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.